Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
quercetin-7-isopropyl (7-O-isopropylquercetin) is a semi-synthetic alkylated derivative of the natural flavonoid quercetin. By substituting the hydroxyl group at the C-7 position with an isopropyl ether group, the molecule exhibits enhanced lipophilicity and potentially improved metabolic stability compared to parent quercetin. It is primarily recognized for its anti-carbonyl and oxidative stress (anti-COS) properties, specifically its ability to protect neuronal cells from carbonyl stress induced by toxic aldehydes such as acrolein. This compound is also a critical structural component and synthetic intermediate for polyunsaturated lipophenols, such as quercetin-3-docosahexaenoic acid-7-isopropyl, which are being developed as multifunctional agents for neurodegenerative disorders like Alzheimer's disease. Research conducted by the CNRS and the University of Montpellier has highlighted its potential in alleviating harmful mechanisms associated with neuronal cell loss.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercetin-7-isopropyl.